- Raw materials
- Other substances
- Phenyl aminosalicylate
Phenyl aminosalicylate API Manufacturers & Suppliers
0 verified results
All Phenyl aminosalicylate data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Phenyl aminosalicylate | CAS No: 133-11-9 | GMP-certified suppliers
A medication that serves as a salicylate derivative with potential anti-inflammatory applications, primarily utilized in specialized or research pharmaceutical settings.
Therapeutic categories
Product Snapshot
- Phenyl aminosalicylate is an oral small molecule formulation
- It is primarily utilized in the treatment of tuberculosis and related infections
- The compound is approved for use in key regulatory markets including the FDA and EMA
Clinical Overview
Despite its established chemical classification and approval status, detailed clinical indications and pharmacodynamic profiles for phenyl aminosalicylate are not well documented in publicly available literature. Consequently, specific therapeutic uses and pharmacological mechanisms of action remain undetermined. Its structural features suggest potential interactions typical of salicylate derivatives; however, the absence of direct pharmacological data precludes definitive conclusions regarding its mechanism.
Key pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME) parameters, have not been comprehensively reported. As such, the compound's bioavailability, metabolic pathways, half-life, and elimination routes require further elucidation to inform clinical application and dosing considerations.
Safety and toxicity profiles are not explicitly characterized for phenyl aminosalicylate. Given the general properties of related salicylate compounds, monitoring for common adverse effects, including hypersensitivity reactions and gastrointestinal irritation, may be prudent. However, specific toxicological data, contraindications, or warnings for this compound are not currently available.
There are no widely recognized commercial brand names or standardized usage contexts associated with phenyl aminosalicylate in current pharmaceutical markets. Its application appears limited or specialized, possibly restricted to research or niche therapeutic areas.
When sourcing phenyl aminosalicylate as an active pharmaceutical ingredient (API), emphasis should be placed on verifying compliance with relevant pharmacopeial standards and regulatory requirements. Quality considerations must include impurity profiling, stability testing, and confirmation of chemical identity to ensure consistent batch integrity. Due to limited public information, procurement from qualified manufacturers with comprehensive documentation and validated quality systems is advisable.
Identification & chemistry
| Generic name | Phenyl aminosalicylate |
|---|---|
| Molecule type | Small molecule |
| CAS | 133-11-9 |
| UNII | 52936SIP7V |
| DrugBank ID | DB06807 |
Formulation & handling
- Phenyl aminosalicylate is a small molecule suitable for oral formulation due to its low water solubility and moderate lipophilicity.
- The compound's polycyclic depside structure may impact chemical stability, suggesting controlled storage conditions to maintain integrity.
- Handling precautions should consider its limited aqueous solubility, potentially requiring solubilizing agents or formulation strategies to enhance bioavailability.
Regulatory status
Phenyl aminosalicylate is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
